| __timestamp | Catalyst Pharmaceuticals, Inc. | Opthea Limited |
|---|---|---|
| Wednesday, January 1, 2014 | 10117774 | 3401685 |
| Thursday, January 1, 2015 | 11801342 | 4284228 |
| Friday, January 1, 2016 | 11369941 | 3581295 |
| Sunday, January 1, 2017 | 11375237 | 4838300 |
| Monday, January 1, 2018 | 19919204 | 24891534 |
| Tuesday, January 1, 2019 | 18842752 | 31347891 |
| Wednesday, January 1, 2020 | 16496715 | 17480747 |
| Friday, January 1, 2021 | 16936000 | 34710152 |
| Saturday, January 1, 2022 | 19789000 | 108459978 |
| Sunday, January 1, 2023 | 93150000 | 181563523 |
| Monday, January 1, 2024 | 176326321 |
Igniting the spark of knowledge
In the ever-evolving landscape of pharmaceuticals, research and development (R&D) budgets are a key indicator of a company's commitment to innovation. Over the past decade, Opthea Limited and Catalyst Pharmaceuticals, Inc. have demonstrated contrasting strategies in their R&D investments. From 2014 to 2023, Opthea Limited's R&D expenses surged by over 5,200%, peaking in 2023 with a remarkable 181 million USD. This reflects their aggressive pursuit of groundbreaking therapies. In contrast, Catalyst Pharmaceuticals, Inc. maintained a more conservative approach, with a steady increase culminating in a 931% rise by 2023. Notably, 2023 marked a significant leap for Catalyst, with R&D expenses reaching 93 million USD, a tenfold increase from 2014. These trends underscore the dynamic nature of pharmaceutical innovation, where strategic R&D investments can shape the future of healthcare.
Comparing Innovation Spending: GSK plc and Catalyst Pharmaceuticals, Inc.
Comparing Innovation Spending: Incyte Corporation and Opthea Limited
R&D Spending Showdown: Intra-Cellular Therapies, Inc. vs Opthea Limited
BioMarin Pharmaceutical Inc. vs Opthea Limited: Strategic Focus on R&D Spending
Research and Development: Comparing Key Metrics for Lantheus Holdings, Inc. and Catalyst Pharmaceuticals, Inc.
Comparing Innovation Spending: Corcept Therapeutics Incorporated and Opthea Limited
Who Prioritizes Innovation? R&D Spending Compared for Opthea Limited and CRISPR Therapeutics AG
Opthea Limited vs HUTCHMED (China) Limited: Strategic Focus on R&D Spending
Analyzing R&D Budgets: Opthea Limited vs Amphastar Pharmaceuticals, Inc.
TG Therapeutics, Inc. vs Catalyst Pharmaceuticals, Inc.: Strategic Focus on R&D Spending
Research and Development: Comparing Key Metrics for Verona Pharma plc and Catalyst Pharmaceuticals, Inc.
R&D Spending Showdown: Catalyst Pharmaceuticals, Inc. vs Iovance Biotherapeutics, Inc.